LGVN - Longeveron partners with Kinesiometrics to create an App to measure physical responses to cell therapy

Longeveron (LGVN -2.4%) enters agreement with Kinesiometrics to provide a cutting-edge, digital data-driven solution for objective real-time measurement of functional capacity and quality of life in company's clinical studies. The data is accessible to the company and recipients of Lomecel-B via an Application downloadable on the subjects’ mobile phones. “We are extremely excited about the collaboration with Kinesiometrics as it fits perfectly with our strategic vision to develop biological solutions for aging. The Kinesiometrics platform has the potential to help us advance our clinical development program and gain greater insights into how Lomecel-B impacts patient’s quality of life and functional capacity. The new data generated may help with FDA regulatory filings and is highly consistent with the introduction of digital wearable technology into advancement of novel therapeutic strategies.” said Geoff Green, CEO.

For further details see:

Longeveron partners with Kinesiometrics to create an App to measure physical responses to cell therapy